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Abstract
Background: Emergence of rmtB-positive Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae
(KPC-KP) poses a great threat to antimicrobial treatment options.
Methods: From January 2010 to December 2010, non-duplicate KPC-KP isolates from our hospital were screened
for rmtB and multiple other resistance determinants with PCR. Subsequent studies included MIC determination,
PFGE, and multilocus sequence typing. Records from patients with KPC-KP isolated were retrospectively reviewed.
Comparisons of molecular and clinical characteristics between rmtB-positive and rmtB–negative isolates were
systematically performed, as well as the environmental colonization study in ICU wards.
Results: A total of 84 KPC-KP strains were collected, including 48 rmtB-positive KPC-KP (RPKP) and 36 rmtB-negative
KPC-KP (RNKP) isolates. All KPC-KP isolates were multidrug resistant, with colistin and tigecycline being the most
active agents. Compared with RNKP, RPKP displayed a much severer resistance phenotype. Susceptibility rates for
amikacin (0% for RPKP versus 88.9% for RNKP, p < 0.01), fosfomycin (8.5% for RPKP versus 88.9% for RNKP, p < 0.01),
and minocycline (6.7% for RPKP versus 52.8% for RNKP, p < 0.01), were all significantly lower in RPKP strains. Isolates
belonging to PFGE pulsetype A and sequence type 11 were predominant in both groups, including 39 (81.3%)
RPKP and 22 (61.1%) RNKP isolates. Nevertheless, RNKP showed more complex genetic backgrounds compared with
RPKP. Diverse clinical characteristics were found in both cohorts, however, no significant differences were observed
between RPKP and RNKP patients.
Conclusions: RPKP strains have spread widely and gradually replaced RNKP in our hospital. They seemed to show
much severer resistance phenotypes compared with RNKP and had a bigger dissemination potential. Prudent use
of available active agents combined with good control practices is therefore mandatory.
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Background
During the past 10 years, Chinese clinicians have wit-
nessed a dramatic increase in the rates of carbapenem re-
sistance among clinical isolates of Klebsiella pneumoniae.
According to Mohnarin and CHINET, two leading anti-
microbial resistance surveillance networks in China that
cover all regions except Tibet, carbapenem resistance rates
among K. pneumoniae escalated from 0.7% in 2000 to
2.9% in 2009 [1]. Moreover, in a university hospital in
Shanghai, the incidence of carbapenem-resistant K. pneu-
moniae in 2009 reached 12.9% [2]. In China, carbapenem
resistance in K. pneumoniae has mainly resulted from the
rapid dissemination of Klebsiella pneumoniae carbapene-
mase (KPC) [2-4], and ST11 was demonstrated to be
the dominant clone of KPC-producing K. pneumoniae
(KPC-KP) [4].
KPC-KP isolates were usually multidrug resistant, but
might remain susceptible to one or more aminoglycoside
agents as well as to colistin and/or tigecycline [4-6].
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Nevertheless, 16S rRNA methylases (ArmA and RmtB)
were reported in a few KPC-producing Enterobacteriaceae
recently, conferring high level resistance to almost all clin-
ically important aminoglycosides [7-9]. Co-production of
16S rRNA methylases in KPC-producing pathogens and
their potential spread could leave few choices for anti-
microbial treatment.
Since its first isolation in 2007 [10], KPC-KP has been
increasingly emerging at our hospital. Most of these iso-
lates were still susceptible to one or more aminoglycoside
antibiotics until 2009; nevertheless, high-level aminoglyco-
side resistance has emerged and gradually become preva-
lent in the last two years (data not shown). In May 2010,
an Enterobacter amnigenus as well as a K. pneumoniae
isolate, both co-producing blaKPC and rmtB on a single
plasmid, were simultaneously identified from a patient in
our neurosurgery ward. And a small outbreak of KPC-
RmtB-producing K. pneumoniae was revealed in the
neurosurgery department [7]. This promoted us to per-
form a hospital-wide screening of rmtB gene in KPC-KP
strains. Our study focused on the comparisons of micro-
biological, molecular and clinical characteristics between
rmtB-positive KPC-KP (RPKP) and rmtB-negative KPC-
KP (RNKP) isolates.
Methods
Bacterial isolates and patients
Between January 2010 and December 2010, all clinical K.
pneumoniae isolates exhibiting non-susceptibility to car-
bapenems (inhibition diameter <16 mm for at least one of
meropenem and imipenem with the help of disc diffusion
method) were obtained in the First Affiliated Hospital,
School of Medicine, Zhejiang University. This hospital is a
2500-bed tertiary-care academic medical center receiving
about 2 560 000 outpatients and 71 000 inpatients annu-
ally. Detection of blaKPC and rmtB genes was conducted
by PCR and subsequent sequencing based on established
methods [4,11]. A case patient was defined as patient with
KPC-KP (including RPKP and RNKP) isolated from clin-
ical specimens during our study period. If more than one
isolate were obtained from a patient, only the initial isolate
was submitted.
Cohort study
A retrospective observational cohort study was conducted
between RPKP and RNKP patients. Detailed clinical infor-
mation of case patients was extracted from their medical
records and follow-up was possible until discharge from
our hospital or death. Isolates identified during the first
72 h after admission were characterized as imported,
whereas those identified >72 h after admission were deter-
mined as nosocomial transmission during the current
hospitalization. Infection was defined according to the cri-
teria from Centers for Disease Control and Prevention
(CDC)/National Healthcare Safety Network [12]. Patients
without infection but with KPC-KP isolated were consid-
ered as colonized. The study was approved by the Institu-
tional Review Board of our hospital.
Bacterial identification and susceptibility testing
Species identification was performed using the Vitek 2
system (bioMerieux, France). MICs of various antimicro-
bials were determined by agar dilution method and
results were interpreted according to the criteria recom-
mended by Clinical and Laboratory Standards Institute
(CLSI) 2010 [13]. With regard to tigecycline, breakpoint
for Enterobacteriaceae based on FDA was used (MIC
≤2 μg/mL as susceptible). And concentration of 4 μg/mL
was used as the breakpoint of resistance for colistin [14].
Molecular typing
Pulse field gel electrophoresis (PFGE) was performed
using XbaΙ restriction enzyme on all clinical isolates and
PFGE profiles were interpreted by the criteria proposed by
Tenover [15]. Multilocus sequence typing (MLST) was
carried out according to protocols on the MLST web-
site for K. pneumoniae (http://www.pasteur.fr/recherche/
genopole/PF8/mlst/Kpneumoniae.html).
PCR testing and DNA sequencing
PCR analysis was conducted to detect a variety of resist-
ance determinants as described previously, including
blaOXA, blaTEM, blaSHV, and blaCTX genes [4,16], six more
16S rRNA methylase-encoding genes (armA, rmtA, rmtC,
rmtD, rmtE and npmA) [11], and plasmid-mediated quin-
olone resistance genes (qnrA, qnrB, qnrS and aac(6’)-Ib-cr)
[16]. The PCR products were subsequently sequenced by
dideoxynucleotide chain-termination method by ABI 377
(ABI, U.S.A.) and sequences were compared with the nu-
cleotide sequences from GenBank (www.ncbi.nlm.nih.gov/
blast/).
Environmental colonization study
A point prevalence survey of environmental colonization
was conducted in the general ICU wards in July 2010 to
probe the potential environmental reservoirs of RPKP.
Environmental surfaces including medical equipments in
the immediate vicinity of patients, communal areas, and
contaminated hands of medical staff on shift, were under
screening. Swab samples were obtained by repeatedly
rubbing designated sites with premoistened swabs. The
swabs were then placed in brain and heart infusion
(BHI) containing meropenem (1 μg/mL) and incubated
overnight at 37°C. Isolated strains were subjected to fur-
ther analysis as clinical isolates as described above.
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Statistical analysis
Comparative analyses were performed using the χ2 test
or the Fischer’s exact test for categoric variables, and
Student’s t test for the continuous variables, as appropri-
ate. A 2-tailed P value of <0.05 was considered to indi-
cate statistical significance. Analyses were done with
SPSS 17.0 (SPSS Inc, Chicago, USA).
Results
A total of 84 KPC-KP isolates were identified during the
study period. Among them, 48 were confirmed to be
RPKP, and the rest RNKP. Medical records were avail-
able for 35 RPKP patients and 29 RNKP patients. Com-
parisons of various clinical characteristics between RPKP
and RNKP patients are presented in Table 1. Most
patients were severely ill and half were from ICU de-
partments. Respiratory tract was the most common site
of infection in both cohorts. Although a majority of
KPC-KP isolates were acquired at our hospital, 7 RNKP
(24.1%) and 4 RPKP isolates (11.4%) were imported. An-
other notably feature was that bed transfers were rather
common among these patients (2.54 times for RPKP
versus 2.52 times for RNKP), even after isolation of
KPC-KP (1.57 times for RPKP versus 1.66 times for
RNKP). Crude mortality was 22.9% among RPKP
patients and 27.6% among RNKP patients, and attribut-
able mortality rates were 19.4% and 17.9%, respectively.
The epidemic curve revealed three phases (Figure 1):
period 1 (January to April), during which sporadic cases
of KPC-KP were identified and RPKP initiated to
emerge; period 2 (May to July), during which a hospital-
wide outbreak of KPC-KP was observed, with dramatic
increase in both RNKP and RPKP isolates, and RPKP
became predominant gradually; period 3 (August to
December), during which high-level epidemic of KPC-KP
persisted, and RPKP overtook RNKP to become the dom-
inant KPC-KP.
KPC-KP isolates were multidrug resistant (Table 2).
They only showed sufficient susceptibility to colistin and
tigecycline (susceptibility rate: 98.8% for colistin and
96.3% for tigecycline). However, RPKP displayed much
severer multidrug resistance phenotypes compared with
RNKP. With regard to aminoglycoside antibiotics,
all RPKP undoubtedly showed high-level resistance,
whereas a majority of RNKP were still susceptible to
at least one of them (88.9% for amikacin; 72.2% for
netilmicin; 47.2% for gentamicin). In addition, RPKP iso-
lates demonstrated significantly lower susceptibility rates
to fosfomycin (8.5% for RPKP versus 88.9% for RNKP,
P < 0.01) and minocycline (6.7% for RPKP versus 52.8%
for RNKP, P < 0.01).
Molecular typing results and resistance determinant
profiles are shown in Table 3. PFGE analysis revealed 10
different pulsetypes (PTs), designated as A-J (Figure 2).
The most widely disseminated PT was A, consisting of
63 clinical isolates (75%). By MLST, 10 distinct sequence
types (STs) were identified, including 3 novel STs
(ST689, ST690, and ST691). ST11 was the predominant
ST, with 68 isolates (80.9%). Most of MLST data were
consistent with results generated by PFGE. ST11-PTA
was the dominant molecular type in both RPKP and
RNKP. However, a greater diversity of STs and more
complicated relatedness between the results of PFGE
and MLST were observed in RNKP, indicating more di-
verse genetic backgrounds in RNKP.
Apart from blaKPC-2 in all isolates and rmtB in RPKP,
blaCTX-M-14, blaSHV-12 and blaTEM-1 were revealed in most
isolates. In addition, four RNKP belonging to ST412 or
ST692 also encoded blaOXA-1–type and blaOXA-10–type
β-lactamases and aac(6’)-Ib-cr, and a single ST689 RNKP
encoded blaOXA-1. Only one RPKP and three RNKP strains
carried qnrS. No other 16S rRNA methylase-encoding
genes were identified.
In total, 210 environmental samples were obtained
from the general ICU department. Among the 210 sam-
ples, only one was RPKP positive, which was identified
from a folder of patient chart from an empty bed with a
RPKP patient discharged. The environmental RPKP was
assigned to ST11-PTA clone, and carried blaCTX-M-14,
blaSHV-12 and blaTEM-1 in addition to blaKPC and rmtB
genes. It also showed similar antibiogram as its clinical
counterparts (data not shown).
Discussion
Nowadays, KPC-KP isolates have become major hospital
pathogens, and their worldwide spread makes them a
great threat to currently available antibiotic-based treat-
ments. Tigecycline, colistin, and aminoglycosides if active,
are agents recommended for severe infections caused by
carbapenemase-producing Enterobacteriaceae [17]. How-
ever, despite of good in vitro activity of colistin and tigecy-
cline against most of these strains, clinical data on their
in vivo efficacy are quite limited [17]. Emergence of tigecy-
cline resistance and colistin resistance during therapy with
these agents is another issue to be considered [18-20]. A
colistin-resistant RNKP isolate was also identified from a
patient in our study, even without history of colistin ther-
apy. Fortunately, a high proportion of KPC-KP isolates still
showed in vitro susceptibility to aminoglycosides [6,21,22],
including most of recently emerging colistin-resistant or
tigecycline-resistant KPC-KP strains [18-20]. The colistin-
resistant isolate found in our study was susceptible to ami-
noglycosides as well. In addition, a more recent study on
KPC-KP bacteriuria demonstrated that treatments includ-
ing aminoglycosides achieved a significantly higher rate of
microbiologic clearance than did treatments with poly-
myxin B or tigecycline [23]. These findings together indi-
cated that aminoglycosides may serve as effective
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Table 1 Univariate analysis for clinical characteristics of patients infected or colonized with RPKP and RNKP isolates
Characteristics Patients with RPKP (n = 35) Patients with RNKP (n = 29) P value
Male sex 28(80.0) 21(72.4) 0.79
Age, mean years ± SD 63 ± 13.8 63 ± 18.9 0.988
Ward
ICU 17(48.6) 17(58.6) 0.68
Medicine 6(17.1) 2(6.9) 0.45
Surgery 12(34.3) 10(34.5) >0.99
Transferred from another hospital 15(42.9) 13(44.8) 0.92
Total length of stay in any hospital before isolation of KPC-KP,
mean days ± SD 18.7 ± 15.1 16.2 ± 15.0 0.525
Total length of stay until discharge or death, mean days ± SD 36.1 ± 22.2 35.6 ± 22.4 0.94
Route of acquisition of KPC-KP 0.203
Imported 4(11.4) 7(24.1) –
Acquired in our hospital 31(88.6) 22(75.9) –
Site of KPC-KP isolation
Bronchial secretion 15(42.9) 12(41.4) >0.99
Blood 6(17.1) 10(34.5) 0.27
Drainage 7(20.0) 6(20.7) >0.99
Urine 4(11.4) 1(3.4) 0.38
Cerebrospinal fluid 2(5.7) 0 –
Pus 1(2.9) 0 –
Infection 31(88.6) 28(96.6) 0.37
Median APACHEII score 17(2–37) 16(2–35) 0.129
Median Charlson score 2(0–10) 2(0–5) 0.233
Invasive procedures
Surgery within a month 16(45.7) 15(51.7) 0.83
Mechanical ventilation 18(51.4) 18(62.1) 0.68
Renal replacement therapy 11(31.4) 9(31.0) >0.99
Drainage catheters 33(94.3) 20(68.9) 0.46
Total times of bed transfer during this hospitalization, mean times ± SD 2.54 ± 1.31 2.52 ± 1.38 0.94
Total times of bed transfer after KPC-KP isolation, mean times ± SD 1.57 ± 0.95 1.66 ± 0.94 0.72
Antibiotic therapy during the last month
Piperacillin-tazobactam 6(17.1) 5(17.2) >0.99
Third-generation cephalosporins 21(60.0) 21(72.4) 0.69
Carbapenems 21(60.0) 13(44.8) 0.53
Quinolones 10(28.6) 3(10.3) 0.22
Fosfomycin 2(5.7) 1(3.4) >0.99
Aminoglycosides 0 1(3.4) –
Minocycline 1(2.9) 0 –
Crude mortality 8(22.9) 8(27.6) 0.77
Attributable mortality 6(19.4)a 5(17.9) 0.88
Footnotes. Data are no. (%) of patients. RPKP, rmtB-positive KPC-producing K. pneumoniae; RNKP, rmtB-negative KPC-producing K. pneumoniae; APACHE II, Acute
Physiology and Chronic Health Evaluation II score; ICU, intensive care unit; SD, standard deviation.
a the denominator was the number of patients with infection.
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antimicrobials in treating KPC-KP infections. Emergence
of aminoglycoside-resistance in KPC-KP isolates therefore
threatens the viability of this therapeutic option and fur-
ther limits choices of available active agents.
In the present study, we documented the emergence
and rapid spread of rmtB-positive KPC-KP (RPKP) in a
Chinese university hospital. Due to the presence of rmtB
gene, RPKP isolates showed high level resistance to almost
all clinical available aminoglycosides. In addition, RPKP
were usually resistant to many more clinically useful anti-
microbials compared with RNKP, including minocycline
and fosfomycin, which could serve as salvage remedies
alone or in combination for infections due to carbapenem-
resistant K. pneumoniae [21,24]. The fact that RPKP only
exhibited sufficient susceptibility to colistin and tigecycline
has led to the dead-end of antimicrobial therapy in our
hospital, since both colistin and tigecycline were unavail-
able in China during the study period.
Our results are concordant with the observation that
ST11 was the dominant clone of KPC-KP in Mainland
China [4]. ST11 is a single-locus variant of the inter-
national hyper-epidemic lineage ST258, and has also been
identified in Singapore and more recently in Taiwan
[25,26]. It is increasingly recognized that ST258 is the
Figure 1 Temporal distribution of patients infected or colonized with Klebsiella pneumoniae carbapenemase 2 (KPC)-producing
K. pneumoniae during the study period. RPKP and RNKP are shown separately. RPKP, rmtB-positive KPC-producing K. pneumoniae; RNKP,
rmtB-negative KPC-producing K. pneumoniae.
Table 2 Susceptibility profiles of 48 RPKP and 36 RNKP isolates
Antimicrobial
agents
MIC range, μg/mL MIC50, μg/mL MIC90, μg/mL Susceptible percentage,% P-
valueRNKP(n = 48) RPKP(n = 36) RNKP RPKP RNKP RPKP all isolates RNKP RPKP
Imipenem 4-256 8-128 128 128 256 128 0 0 0 —
Meropenem 2-256 4-128 64 64 128 64 0 0 0 —
Ertapenem 4-512 8-512 128 128 256 128 0 0 0 —
Cefotaxime 16 to >512 16 to >512 256 >512 512 >512 0 0 0 —
Cefepime 4-256 4-512 128 128 128 512 11.1 11.1 11.1 >0.99
Gentamicin 1 < to >512 256 to >512 8 >512 128 >512 21 47.2 0 <0.01
Netilmicin 1 to >512 256 to >512 8 >512 256 >512 32.1 72.2 0 <0.01
Amikacin 2 to >512 256 to >512 4 >512 >512 >512 39.5 88.9 0 <0.01
Tetracycline 4 to >512 8-256 16 32 512 128 3.7 8.3 0 0.084
Minocycline 2-128 4-32 4 8 64 32 27.2 52.8 6.7 <0.01
Ciprofloxacin 0.25 < to 64 2-64 64 64 64 64 6 13.9 0 0.015
Ofloxacin 0.25 < to 64 1-64 64 64 64 64 8.4 13.9 4.3 0.23
Tigecycline 0.5-4 0.5-4 2 2 2 2 96.3 97.2 95.6 >0.99
Colistin 0.25-256 0.5-2 1 1 2 2 98.8 97.2 100 0.44
Fosfomycin 1 to >1024 2 to > 1024 16 >1024 64 >1024 43.4 88.9 8.5 <0.01
Footnotes. RPKP, rmtB-positive KPC-producing K. pneumoniae; RNKP, rmtB-negative KPC-producing K. pneumoniae; MIC, minimum inhibitory concentration; MIC50,
MIC required to inhibit the growth of 50% of organisms; MIC90, MIC required to inhibit the growth of 90% of organisms.
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predominant clone of KPC-KP across the whole world
and has caused outbreaks in many countries [5,6,22]. Fur-
thermore, ST258 has extended to the recently reported
colistin-resistant KPC-KP [18,27]. In the present study,
ST11 KPC-KP also seemed to show dissemination advan-
tage over other clones and be good colonizers to capture
and accumulate resistance determinants. Of particular
concern is that increasing prevalence of RPKP coincides
with decreasing prevalence of RNKP in our hospital,
which might suggest a bigger dissemination advantage of
ST11 RPKP over ST11 RNKP, even in the absence of se-
lective pressure. Another particular concern is the fact
that 3 RPKP isolates (all belonged to ST11-PTA) were
imported from other local hospitals, suggesting the pres-
ence of inter-hospital dissemination of this extremely
multi-drug resistant pathogen. This indicates a dangerous
possibility that ST11 RPKP clone might spread widely out-
side our hospital in the future.
The fact that most RPKP isolates belonged to ST11-
PTA and were acquired in our hospital indicates the possi-
bility that monoclonal cross transmission is the main
mode of spreading. However, the failure to find a common
environmental reservoir indicated patient-to-patient trans-
mission as the main mechanism of RPKP spread in our
study. Frequent bed transfers of case patients, particularly
after isolation of RPKP, combined with lack of adequate
preventive measures might have facilitated this process. It
is also worth mentioning that the only one environmental
Table 3 STs, PFGE pulsetypes, and distribution of resistance determinants in 48 RPKP and 36 RNKP isolates
Groups MLST PFGE Isolate Resistance determinants
RPKP (n = 48) 11 A 39 blaCTX-M-14-blaKPC-rmtB-blaSHV-blaTEM
11 B1 4 blaCTX-M-14-blaKPC-rmtB-blaSHV-blaTEM
11 E 1 blaCTX-M-14-blaKPC-rmtB-blaSHV-blaTEM
11 I 1 blaCTX-M-14-blaKPC-rmtB-blaSHV-blaTEM
542 D 1 blaCTX-M-3-blaKPC-rmtB-blaTEM
655 C 2 blaKPC-rmtB-blaSHV-blaTEM (one strain encoded qnrS)
RNKP (n = 36) 11 A 22 blaCTX-M-14-blaKPC-blaSHV-blaTEM (two strains encoded qnrS)
11 H1 1 blaCTX-M-14-blaKPC-blaSHV-blaTEM
214 A 1 blaCTX-M-14-blaKPC-blaSHV
412 A 1 blaCTX-M-14-blaKPC-blaSHV-blaTEM-blaOXA-1-blaOXA-10-aac(6)-Ib
412 J 1 blaCTX-M-14-blaKPC-blaSHV-blaOXA-1-blaOXA-10-aac(6)-Ib
412 H2 1 blaCTX-M-14-blaKPC-blaSHV-blaOXA-1-blaOXA-10-aac(6)-Ib
494 F1 4 blaCTX-M-14-blaKPC-blaSHV-blaTEM
494 B2 1 blaKPC-blaSHV-blaTEM
689 E 1 blaCTX-M-3-blaKPC-blaSHV-blaTEM-blaOXA-1
690 F1 1 blaKPC-blaSHV-blaTEM
691 F2 1 blaKPC-blaSHV-blaTEM
161 G 1 blaKPC-blaSHV-blaTEM-blaOXA-1-blaOXA-10-qnrS- aac(6)-Ib
Footnotes. RPKP, rmtB-positive KPC-producing K. pneumoniae; RNKP, rmtB-negative KPC-producing K. pneumoniae; MLST, multilocus sequence typing; PFGE, pulse
field gel electrophoresis; STs, sequence types.
Figure 2 PFGE patterns of KPC-producing K. pneumoniae
representing all pulsetypes of KPC-KP isolates. Lanes A to J,
pulsetypes A to J.
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RPKP isolate was identified from a decontaminated empty
bed, which obliged us to enhance the effectiveness of de-
contamination procedures in our hospital.
Infections with pathogens resistant to more antibiotics
have been reported to be associated with poorer functional
status and worse outcomes [28,29]. However, in our study,
despite of diverse clinical characteristics, no significant dif-
ferences were observed between the two cohorts. The
similar clinical characteristics between RPKP and RNKP
patients were likely multifactorial. Firstly, patients in both
cohorts were at poor functional status, with severe under-
lying diseases and highly vulnerable to the colonization or
infection of multidrug resistant pathogens. Secondly,
RPKP and RNKP were both extremely drug-resistant
pathogens. They showed sufficient susceptibility only to
colistin and tigecycline. However, neither of them was
readily available in China during our study period. Finally,
although most RNKP (88.9%) were susceptible to at least
one aminoglycoside in vitro, treatment containing amino-
glycoside agents was very limited in our hospital, due to
limited data on their in-vivo efficacy on KPC-KP infec-
tions and their nephrotoxicity [30]. Only three patients
with RNKP were treated with antimicrobial regimens con-
taining aminoglycosides in our study, but all of them had
good clinical outcomes (data not shown).
Conclusions
In summary, we documented the emergence and wide dis-
semination of rmtB-positive KPC-KP in a Chinese univer-
sity hospital. These isolates showed much severer
resistance phenotypes compared with their rmtB-negative
counterparts and seemed to disseminate more easily,
representing a major threat for hospitalized patients. More-
over, patients suffered from RPKP infections were usually
severely ill and ended up with rather high attributable mor-
tality. These results, together with the fact that discovery of
new antibiotics is reduced in recent years, suggest that pru-
dent and conservative use of available active agents com-
bined with good control practices are mandatory.
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